Krystal Biotech, Inc. KRYS Accrued rebates
Accrued rebates at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept krys:AccruedRebatesCurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accrued rebates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accrued rebates?
- Krystal Biotech, Inc. (KRYS) reported accrued rebates of $70.72M in Q1 2026.
- How has Krystal Biotech, Inc.'s accrued rebates changed year-over-year?
- Krystal Biotech, Inc.'s accrued rebates increased by 49.2% year-over-year, from $47.41M to $70.72M.
- What is the long-term trend for Krystal Biotech, Inc.'s accrued rebates?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s accrued rebates has grown at a 212.0% compound annual growth rate (CAGR), from $5.98M to $58.18M.
- What does accrued rebates mean?
- Estimated money the company owes back to customers based on sales agreements.
- How do you interpret accrued rebates?
- An increase often correlates with higher sales volume or changes in pricing strategy, while a decrease may suggest lower rebate obligations or changes in commercial terms.
- How does accrued rebates compare across companies?
- Highly specific to pharmaceutical and consumer goods companies; peers will show similar accruals based on their commercialization stage.